Galectin Other Non Cash Items from 2010 to 2024

GALT Stock  USD 1.15  0.28  32.18%   
Galectin Therapeutics Other Non Cash Items yearly trend continues to be comparatively stable with very little volatility. Other Non Cash Items will likely drop to about 566.5 K in 2024. From the period from 2010 to 2024, Galectin Therapeutics Other Non Cash Items quarterly data regression had r-value of  0.11 and coefficient of variation of  580.93. View All Fundamentals
 
Other Non Cash Items  
First Reported
2001-03-31
Previous Quarter
141 K
Current Value
M
Quarterly Volatility
1.5 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Galectin Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galectin Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 40 M, Interest Expense of 2.7 M or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0016 or Days Sales Outstanding of 0.0. Galectin financial statements analysis is a perfect complement when working with Galectin Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Galectin Therapeutics Correlation against competitors.
For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

Latest Galectin Therapeutics' Other Non Cash Items Growth Pattern

Below is the plot of the Other Non Cash Items of Galectin Therapeutics over the last few years. It is Galectin Therapeutics' Other Non Cash Items historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galectin Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Non Cash Items10 Years Trend
Pretty Stable
   Other Non Cash Items   
       Timeline  

Galectin Other Non Cash Items Regression Statistics

Arithmetic Mean584,236
Geometric Mean594,644
Coefficient Of Variation580.93
Mean Deviation1,887,145
Median489,000
Standard Deviation3,394,008
Sample Variance11.5T
Range14.5M
R-Value0.11
Mean Square Error12.2T
R-Squared0.01
Significance0.68
Slope86,946
Total Sum of Squares161.3T

Galectin Other Non Cash Items History

2024566.5 K
20231.1 M
2022-147 K
2021489 K
201987 K
2018348 K
201745 K

About Galectin Therapeutics Financial Statements

Galectin Therapeutics shareholders use historical fundamental indicators, such as Other Non Cash Items, to determine how well the company is positioned to perform in the future. Although Galectin Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Galectin Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Galectin Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Other Non Cash Items1.1 M566.5 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.